Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 8596867.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate the usefulness of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (Mn-DPDP) in magnetic resonance (MR) imaging of cirrhotic livers. Fifty-eight patients (mean age, 58.8 years), 29 with and 29 without cirrhosis, underwent MR imaging before and after intravenous administration of 5 mumol/kg Mn-DPDP. Enhancement effects were assessed quantitatively and qualitatively. Histologic confirmation was obtained in 51 patients. Liver parenchyma in both patient groups enhanced significantly on T1-weighted spin-echo and gradient-recalled-echo (GRE) images (P < .01). However, cirrhotic livers enhanced significantly less than noncirrhotic livers on T1-weighted GRE images (P < .05). Fourteen cirrhotic livers had heterogeneous enhancement of parenchyma; enhancement was more prominent on GRE images. Decreased enhancement was seen in patients with confluent fibrosis (n = 5), diffuse fibrosis (n = 6), and siderotic regenerating nodules (n = 4). Increased enhancement was seen in patients with benign regenerating nodules (n = 4). Mn-DPDP is useful in patients with cirrhosis.
Medical subject headings
- Edetic Acid
- Liver
- Liver Cirrhosis
- Magnetic Resonance Imaging
- Pyridoxal Phosphate